Clinical trial · Interventional
The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome
The Efficacy and Safety Study of Tung's Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial
NCT02729545CI-TRIAL-00041051completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the efficacy and safety in improving ovarian function of polycystic ovarian syndrome in adults. Half of patients will receive Tung's acupuncture therapy, while the other half will receive Diane-35(CPA/EE) as the control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyproterone acetate/ethinylestradiol (CPA/EE) | Drug | — | UNRESOLVED |
| Tung's acupuncture | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tung's acupuncture
- description
- The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
- interventionNames
- Other: Tung's acupuncture
- type
- ACTIVE_COMPARATOR
- label
- CPA/EE
- description
- Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
- interventionNames
- Drug: Cyproterone acetate/ethinylestradiol (CPA/EE)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: 1. Chinese; 2. 18-45 years old; 3. to meet the diagnostic criteria for polycystic ovary syndrome; 4. no need for pregnancy in the next six months; 5. volunteering to join this research and give informed consent prior to receiving treatment. Exclusion Criteria: 1. hypertensive patients with blood pressure exceed 160/100 mmHg; 2. a history of thrombosis,cerebrolvascular diseases, cancer, liver disease or liver dysfuction, hyperlipidemia, mental disorder, and severe infection; 3. having taken any pharmacological treatments affecting reproductive endocrine system; 4. having received acupuncture in the previous three months; 5. smoking more than 15 cigarettes per day; 6. having pacemakers, metal allergies or severe fear of acupuncture.
References
Publications (0)
Data not yet available
No reference posted for this study.